Literature DB >> 7602431

Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells.

M J Fritzler1, B J Miller.   

Abstract

The objective of the study was to determine the sensitivity and specificity of an indirect immunofluorescence (IIF) assay using transfected HEp-2 cells to detect anti-SS-A/Ro autoantibodies in human sera. Seventy-three sera having SS-A/Ro autoantibodies as determined by double immunodiffusion (ID) and immunoblotting (IB) were tested by IIF on a HEp-2 cell substrate that had been transfected with a full-length cDNA encoding a human 60 kD SS-A/Ro autoantigen. Controls included 30 normal human sera and 50 sera with a variety of other antinuclear antibodies. Prototype human and rabbit sera directed against the 60 kD SS-A/Ro antigen produced intense speckled nuclear and nucleolar staining of transfected cells. Sixty-nine of 73 (95%) SS-A/Ro positive sera also produced this characteristic staining pattern. The endpoint autoantibody titers on transfected cells was fivefold greater than on untransfected cells. The 30 normal human sera and the 50 sera with other antinuclear antibodies did not produce this characteristic staining. Six of 32 (19%) unselected sera that were sent for autoantibody testing had reactivity with transfectants by IIF. Four of the six sera were confirmed to have anti-SS-A/Ro antibodies by ID and 5/6 by IB. By contrast, only three of these sera were scored as having a staining pattern compatible with SS-A/Ro antibodies by IIF on standard HEp-2 substrates. We conclude that SS-A/Ro autoantibodies can be detected by an IIF assay using a HEp-2 cell substrate transfected with a SS-A/Ro cDNA. This new substrate detects SS-A/Ro antibodies that were not identified on standard HEp-2 substrates and by other immunoassays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7602431     DOI: 10.1002/jcla.1860090312

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  11 in total

1.  Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing.

Authors:  I Peene; L Meheus; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Antinuclear antibody (ANA) profile testing of ANA- positive patients.

Authors:  G S Hauksdóttir; T Jónsson; O J Mellbye
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

3.  Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate.

Authors:  Marvin J Fritzler; Cheryl Hanson; Joan Miller; Theophany Eystathioy
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

Review 4.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

5.  An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing.

Authors:  Ada Man; Kam Shojania; Carmen Phoon; Jason Pal; Monika Hudoba de Badyn; David Pi; Diane Lacaille
Journal:  Clin Rheumatol       Date:  2013-01-06       Impact factor: 2.980

Review 6.  Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies.

Authors:  Anne E Tebo
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 7.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

8.  A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Authors:  Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton
Journal:  Clin Rheumatol       Date:  2007-06-15       Impact factor: 2.980

9.  Clinical and serological features of patients with autoantibodies to GW/P bodies.

Authors:  Rahima A Bhanji; Theophany Eystathioy; Edward K L Chan; Donald B Bloch; Marvin J Fritzler
Journal:  Clin Immunol       Date:  2007-09-17       Impact factor: 3.969

10.  Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Authors:  Simone Mader; Viktoria Gredler; Kathrin Schanda; Kevin Rostasy; Irena Dujmovic; Kristian Pfaller; Andreas Lutterotti; Sven Jarius; Franziska Di Pauli; Bettina Kuenz; Rainer Ehling; Harald Hegen; Florian Deisenhammer; Fahmy Aboul-Enein; Maria K Storch; Peter Koson; Jelena Drulovic; Wolfgang Kristoferitsch; Thomas Berger; Markus Reindl
Journal:  J Neuroinflammation       Date:  2011-12-28       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.